8.37
-0.03 (-0.36%)
| Penutupan Terdahulu | 8.40 |
| Buka | 8.37 |
| Jumlah Dagangan | 1,819,693 |
| Purata Dagangan (3B) | 1,030,025 |
| Modal Pasaran | 625,087,232 |
| Harga / Buku (P/B) | 8.85 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| EPS Cair (TTM) | -1.03 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.34% |
| Nisbah Semasa (MRQ) | 4.90 |
| Aliran Tunai Operasi (OCF TTM) | -28.53 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -13.17 M |
| Pulangan Atas Aset (ROA TTM) | -39.21% |
| Pulangan Atas Ekuiti (ROE TTM) | -100.13% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Corvus Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | 0.5 |
| Purata | 1.25 |
|
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 3.83% |
| % Dimiliki oleh Institusi | 48.27% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Adams Street Partners Llc | 30 Sep 2025 | 3,275,616 |
| Vivo Capital, Llc | 30 Sep 2025 | 2,234,566 |
| Sphera Funds Management Ltd. | 30 Sep 2025 | 407,709 |
| Julat 52 Minggu | ||
| Median | 16.00 (91.16%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barclays | 13 Oct 2025 | 16.00 (91.16%) | Beli | 7.11 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |